MarketMoodz
AORT — Artivion, Inc.
Is AORT overbought or oversold? Here is the current MarketMoodz read.
Artivion, Inc. (AORT) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Devices) last closed at $28.82. The rating moved from Neutral to Overbought on August 18, 2026.
- Public ratingOverbought (as of August 19, 2026)
- Last close$28.82
- Last changeMoved from Neutral to Overbought on August 18, 2026
- SectorHealthcare
- IndustryMedical Devices
See all overbought Healthcare stocks →
AI analysis
Artivion, Inc. (AORT) is a medtech company whose near-term performance is closely tied to surgical procedure volumes and adoption of its specialized biologic and surgical products. Market conditions during the review window were steady with balanced order flow and no major macro shocks, leaving company-specific catalysts (product launches, procedure recovery, or strategic activity) as the primary drivers. Cash flow and margin visibility are moderate; upside depends on continued procedure growth, successful product rollouts, and any strategic interest in the medtech sector. Key vulnerabilities include reimbursement/pricing pressure, competition from larger device makers, regulatory or clinical setbacks, and supply-chain risks that could compress revenue and margins.
Key factors
- Exposure to surgical procedure volumes (vascular, cardiac) which drives near-term revenue
- Specialized biologic and surgical product portfolio with differentiated clinical use cases
- Market environment in the last four hours showed balanced order flow and limited macro/headline risk
- Potential strategic/ M&A interest in medtech space could create valuation optionality
- Growth dependent on product adoption, new launches, and stable reimbursement dynamics
- Limited fresh company-specific disclosures in the provided window increases near-term uncertainty
Risks
- Sensitivity to procedure volumes—declines would reduce sales and hurt near-term growth
- Reimbursement pressure and payer rationalization that could compress pricing and margins
- Competitive pressure from larger medtech incumbents and alternative therapies
- Regulatory or clinical setbacks for key products could derail adoption
- Supply-chain disruptions or manufacturing challenges for biologic/surgical products
- Limited publicly-available, company-specific_updates in the window reduces visibility for forecasting
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for AORT — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.